Actinogen Medical Limited (AU:ACW)
ASX:ACW
Top Page
Actinogen Medical
(Sydney:ACW)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.03
▼(-20.00% Downside)
Action:ReiteratedDate:02/14/26
The score is weighed down primarily by weak financial performance (declining revenue, persistent losses, and negative operating/free cash flow). Technical indicators also point to a bearish trend (price below key moving averages and negative MACD). Valuation is not compelling because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Lead clinical asset (xanamem)
Actinogen’s concentrated R&D strategy centers on xanamem, a selective 11β-HSD1 inhibitor with a clear mechanistic rationale for neuropsychiatric and neurodegenerative indications. A single focused lead asset can streamline development priorities and attract targeted partnerships or licensing over the medium term.
Negative Factors
Sharp revenue decline
A near 40% revenue contraction signals weakening top-line traction, reducing internal funding options and increasing reliance on external capital. For a clinical-stage biotech, falling revenue constrains ability to progress multiple programs and raises execution risk over the next 2–6 months without financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Lead clinical asset (xanamem)
Actinogen’s concentrated R&D strategy centers on xanamem, a selective 11β-HSD1 inhibitor with a clear mechanistic rationale for neuropsychiatric and neurodegenerative indications. A single focused lead asset can streamline development priorities and attract targeted partnerships or licensing over the medium term.
Read all positive factors
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$132.89M
Dividend YieldN/A
Average Volume (3M)6.03M
Price to Earnings (P/E)―
Beta (1Y)-0.21
Revenue GrowthN/A
EPS Growth10.91%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,591,539,800
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.74
Price to Sales (P/S)12.48
P/FCF Ratio-9.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.09Price Target Upside116.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.50M
Actinogen Medical Business Overview & Revenue Model
Company Description
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is...
How the Company Makes Money
null...
Actinogen Medical Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.28M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -19.88M | -15.01M | -12.84M | -15.22M | -12.72M | -5.35M |
| Net Income | -17.91M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 10.60M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 366.31K | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 2.23M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 8.37M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -16.45M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -16.41M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.37K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 116.65K | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.05
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
46.40
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.40 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ACW.
Actinogen Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$1.56B | 78.41 | 9.20% | ― | 12.35% | 26.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$32.92M | -5.38 | -19.10% | ― | ― | -672.73% | |
45 Neutral | AU$48.52M | -9.56 | -104.56% | ― | ― | ― | |
43 Neutral | AU$132.89M | -4.28 | -134.14% | ― | ― | 10.91% | |
41 Neutral | AU$97.88M | -2.12 | -30.19% | ― | ― | 63.46% | |
39 Underperform | AU$5.95M | -1.39 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:ACW
Actinogen Medical
0.04
<0.01
8.82%
AU:ENP
Tryptamine Therapeutics
0.03
>-0.01
-9.09%
AU:NEU
Neuren Pharmaceuticals Limited
12.34
1.77
16.75%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:ZLD
Zelira Therapeutics
0.50
0.02
4.17%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.10
0.06
147.50%
Actinogen Medical Corporate Events
Actinogen Director Geoffrey Brooke Increases Stake via Placement
Mar 26, 2026
Actinogen Medical has disclosed a change in the interests of director Dr Geoffrey Brooke following the issue of director placement shares. After shareholder approval on 18 March 2026, Brooke acquired 1,357,857 fully paid ordinary shares indirectly...
Actinogen issues director placement shares after shareholder approval
Mar 26, 2026
Actinogen Medical has issued 15,880,953 new fully paid ordinary shares at $0.042 each to its directors, following shareholder approval of a director placement earlier in March. The company confirmed it has met its continuous disclosure and financi...
Actinogen Medical Seeks ASX Quotation for 15.9 Million New Shares
Mar 26, 2026
Actinogen Medical has applied for quotation of 15,880,953 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of March 26, 2026. The securities form part of a previously announced transaction, signalling an exp...
Actinogen secures $16.8m to fund pivotal Alzheimer’s trial beyond topline results
Mar 18, 2026
Actinogen Medical shareholders approved all six resolutions at a general meeting, including the issuance of placement shares to CEO Dr Steven Gourlay and non-executive directors, who collectively subscribed for A$667,000 at 4.2 cents per share. Th...
Actinogen Extends CEO Loan-Funded Incentive to Support Ongoing Equity Alignment
Mar 15, 2026
Actinogen Medical has amended the loan-funded long-term incentive arrangements for CEO Dr Steven Gourlay by extending the term of a secured, interest-free, limited recourse loan linked to his Loan Plan Shares by two years. The extension applies to...
Actinogen Medical Seeks Quotation for Additional ASX Shares
Mar 5, 2026
Actinogen Medical has applied for quotation on the ASX of 62,014 new ordinary fully paid shares, to be traded under its existing ticker ACW. The securities, issued on March 5, 2026 following the exercise or conversion of existing options or other ...
Actinogen Medical Seeks ASX Quotation for Over 113 Million New Shares
Mar 1, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 113,617,184 new ordinary fully paid shares, expanding its listed securities under the code ACW. The issuance, dated 2 March 2026, forms part of previously announced transactions and...
Actinogen secures $16.8m to fund pivotal Alzheimer’s trial
Feb 27, 2026
Actinogen Medical has completed a $16.8 million capital raise, including $4.8 million from a share purchase plan offered to existing shareholders on the same terms as a prior placement. The new funding lifts its pro forma 31 December 2025 cash bal...
Actinogen Medical Adds 67,499 New Shares to ASX Quotation
Feb 26, 2026
Actinogen Medical Limited, an ASX-listed biotechnology company trading under the code ACW, has applied for quotation of additional ordinary fully paid shares. The move marginally increases its listed equity base, reflecting the conversion or exerc...
Actinogen Medical Widens Half-Year Loss as R&D Spending Rises
Feb 26, 2026
Actinogen Medical reported a modest decline in revenue from ordinary activities for the half year to 31 December 2025, with income of $232,920, largely from interest on cash and short-term deposits. The company remains in an investment phase, post...
Actinogen boosts cash reserves with additional A$1.9m R&D tax rebate
Feb 11, 2026
Actinogen Medical has received a further A$1.87 million research and development tax incentive rebate from the Australian Tax Office, taking its total rebate for the 2025 financial year to A$7.36 million. The latest payment relates to overseas RD ...
Actinogen Medical launches $5m digital-only share purchase plan for retail investors
Feb 9, 2026
Actinogen Medical has launched a share purchase plan offering eligible shareholders in Australia, New Zealand and, in limited cases, the United States the chance to subscribe for up to $30,000 of new shares at $0.042 each without brokerage. The co...
Actinogen launches discounted share purchase plan to fund Alzheimer’s trial
Feb 9, 2026
Actinogen Medical has launched a share purchase plan offering eligible shareholders in Australia and New Zealand, and a limited number of U.S. employees, the chance to buy up to $30,000 of new shares at $0.042 each without brokerage. The offer pri...
Actinogen Raises Capital via Institutional Share Placement to Support Late-Stage Trials
Feb 9, 2026
Actinogen Medical has raised capital by issuing 269,833,333 new fully paid ordinary shares at $0.042 each to sophisticated and institutional investors through an institutional placement. The company has confirmed it remains compliant with its cont...
Actinogen Seeks ASX Quotation for 269.8 Million New Shares
Feb 9, 2026
Actinogen Medical has applied to the ASX for quotation of 269,833,333 new fully paid ordinary shares under code ACW, with an issue date of 9 February 2026. The substantial new share quotation reflects a significant capital move that may impact the...
Actinogen Medical Seeks ASX Quotation for 190,228 New Shares
Feb 5, 2026
Actinogen Medical has applied for quotation on the ASX of 190,228 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The additional securities, to be quoted from 5 February 202...
Actinogen Medical Launches Securities Purchase Plan for Up to 119 Million New Shares
Feb 2, 2026
Actinogen Medical has announced a proposed issue of up to 119,047,619 new ordinary fully paid shares under a securities purchase plan, with a record date of 30 January 2026, an offer closing date of 24 February 2026, and an issue date of 2 March 2...
Actinogen Medical Plans Equity Issue of Up to 15.9 Million Shares
Feb 2, 2026
Actinogen Medical has notified the ASX of a proposed placement or similar issue of up to 15,880,953 new ordinary fully paid shares, with a planned issue date of 18 March 2026. The move signals the company’s intention to raise additional equi...
Actinogen Medical Plans Major Share Placement to Issue Up to 270 Million Shares
Feb 2, 2026
Actinogen Medical Limited has announced a proposed placement of up to 269,833,333 ordinary fully paid shares, with an expected issue date of 9 February 2026. The capital raising, conducted via a placement structure, is intended to expand the compa...
Actinogen Raises Up to A$17m to Fund Pivotal Alzheimer’s Trial Through to Final Results
Feb 2, 2026
Actinogen Medical has secured firm commitments for a share placement of approximately A$12 million at A$0.042 per share, issuing about 285.7 million new shares, with directors including CEO Dr Steven Gourlay committing around A$667,000 subject to ...
Actinogen Advances Late-Stage Alzheimer’s Trial as Interim Analysis Supports Continuing XanaMIA Study
Jan 30, 2026
Actinogen Medical reported that its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial has successfully randomized 247 participants—above the original target—and that an independent Data Monitoring Committee has recommended the...
Actinogen Extends ASX Trading Halt as It Weighs Major Capital Raising
Jan 30, 2026
Actinogen Medical has requested a continuation of its trading halt on the ASX as it considers a proposed material capital raising, following a positive recommendation from its Data Monitoring processes. The halt, approved by the exchange, will rem...
Actinogen Seeks Trading Halt Ahead of Key Interim Alzheimer’s Trial Results
Jan 28, 2026
Actinogen Medical has requested and been granted a trading halt in its securities on the ASX pending the release of results from an interim analysis of its XanaMIA Phase 2b/3 Alzheimer’s disease trial, conducted by an independent Data Monito...
Actinogen Secures $4.3m in Non-Dilutive Funding to Advance Alzheimer’s Trial
Jan 26, 2026
Actinogen Medical has secured a second, non-dilutive tranche of $4.3 million in research and development tax funding from Endpoints Capital, part of a previously announced facility of up to $13.8 million backed by the company’s forecast FY26...
Actinogen Medical Seeks ASX Quotation for New Share Allotment
Jan 22, 2026
Actinogen Medical Limited has applied for quotation on the ASX of 27,566 new fully paid ordinary shares, issued following the exercise or conversion of options or other convertible securities. While a relatively small allotment, the additional quo...
Actinogen Medical Seeks ASX Quotation for Additional Ordinary Shares
Jan 15, 2026
Actinogen Medical Limited has applied to the ASX for quotation of 43,392 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly ex...
Actinogen Courts Global Neuroscience Investors Ahead of Key Xanamem Alzheimer’s Trial Readouts
Jan 11, 2026
Actinogen Medical has dispatched four senior executives to San Francisco to meet investors, analysts and potential partners at the Sachs Neuroscience Innovation Forum and events around the J.P. Morgan Healthcare Conference, aiming to raise the com...
Actinogen Medical Seeks ASX Quotation for Nearly 4.7 Million New Shares
Jan 8, 2026
Actinogen Medical has applied to the ASX for quotation of 4,695,960 new fully paid ordinary shares, to be issued on 8 January 2026 under the code ACW. The additional securities, arising from the exercise or conversion of existing options or other ...
Actinogen Medical Seeks ASX Quotation for Additional Ordinary Shares
Jan 2, 2026
Actinogen Medical Limited has applied to the ASX for quotation of 82,093 new fully paid ordinary shares, to be issued on 2 January 2026 under the ticker ACW. The modest increase in quoted securities reflects the conversion or exercise of existing ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.